MetaCap

Lexaria Bioscience (LEXX) vs Palatin Technologies (PTN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Lexaria Bioscience is the larger company by market cap ($8.5 million vs $8.2 million), about 1.0 times the size. Palatin Technologies converts more of its revenue into profit, with a net margin of -94.9% versus -1686.0%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

LEXX+16.47%PTN-51.89%
+40%-8%-56%
Oct 7, 20261 yearNov 20, 2026
LEXX+21.39%PTN-46.74%
+40%-6%-51%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

LEXX versus PTN key metrics
MetricLEXXPTN
Share price$4.03$4.58
Market cap$8.49M$8.16M
1-day change-10.24%-7.10%
YTD return—-70.22%
1-year return—-79.93%
5-year return—-99.35%
EPS (TTM)$-5.10$-2.96
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$705.92K$8.83M
Revenue growth (YoY)+52.05%—
Net income (latest FY)$-11.90M$-8.38M
Gross margin99.61%—
Operating margin-1683.01%-98.17%
Net margin-1686.00%-94.88%
52-week high$21.60$31.00
52-week low$2.43$4.51
Distance from 52-week high-81.34%-85.23%
Analyst consensusnonestrong_buy
Avg. price target upside+1947.15%+1068.12%
Average volume70.52K71.93K
Shares outstanding2.11M1.78M
Employees725
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Palatin Technologies is more profitable, keeping -94.9 cents of every revenue dollar as net income versus -1686.0 cents for Lexaria Bioscience.

About Lexaria Bioscience

LEXX stock →

Lexaria Bioscience Corp. operates as a biotechnology company.

Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees

About Palatin Technologies

PTN stock →

Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity completed Phase 2 clinical trial; completed a phase 2 of diabetic nephropathy It also provides pl9643 for dry eye disease; and oral PL8177 for inflammatory bowel diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 25 employees

LEXX vs PTN FAQ

Which is bigger, Lexaria Bioscience or Palatin Technologies?

Lexaria Bioscience (LEXX) is larger, with a market capitalization of $8.49M compared with $8.16M for Palatin Technologies (PTN).

Are Lexaria Bioscience and Palatin Technologies in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons